Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group

Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of target...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2015-02, Vol.17 (2), p.180-188
Main Authors: Alexander, Brian M, Galanis, Evanthia, Yung, W K Alfred, Ballman, Karla V, Boyett, James M, Cloughesy, Timothy F, Degroot, John F, Huse, Jason T, Mann, Bhupinder, Mason, Warren, Mellinghoff, Ingo K, Mikkelsen, Tom, Mischel, Paul S, O'Neill, Brian P, Prados, Michael D, Sarkaria, Jann N, Tawab-Amiri, Abdul, Trippa, Lorenzo, Ye, Xiaobu, Ligon, Keith L, Berry, Donald A, Wen, Patrick Y
Format: Article
Language:English
Subjects:
Biomarkers
Brain Neoplasms - diagnosis
Brain Neoplasms - therapy
Clinical Trials as Topic
Endpoint Determination
Glioblastoma - diagnosis
Glioblastoma - therapy
Humans
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/nou154